BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 21084795)

  • 1. Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.
    Miller DK; Bowirrat A; Manka M; Miller M; Stokes S; Manka D; Allen C; Gant C; Downs BW; Smolen A; Stevens E; Yeldandi S; Blum K
    Postgrad Med; 2010 Nov; 122(6):188-213. PubMed ID: 21084795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2.
    Blum K; Chen TJ; Morse S; Giordano J; Chen AL; Thompson J; Allen C; Smolen A; Lubar J; Stice E; Downs BW; Waite RL; Madigan MA; Kerner M; Fornari F; Braverman ER
    Postgrad Med; 2010 Nov; 122(6):214-26. PubMed ID: 21084796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts.
    Blum K; Liu Y; Wang W; Wang Y; Zhang Y; Oscar-Berman M; Smolen A; Febo M; Han D; Simpatico T; Cronjé FJ; Demetrovics Z; Gold MS
    Postgrad Med; 2015 Mar; 127(2):232-41. PubMed ID: 25526228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).
    Blum K; Chen TJ; Downs BW; Bowirrat A; Waite RL; Braverman ER; Madigan M; Oscar-Berman M; DiNubile N; Stice E; Giordano J; Morse S; Gold M
    Postgrad Med; 2009 Nov; 121(6):176-96. PubMed ID: 19940429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS).
    Blum K; Chen TJ; Chen AL; Madigan M; Downs BW; Waite RL; Braverman ER; Kerner M; Bowirrat A; Giordano J; Henshaw H; Gold MS
    Med Hypotheses; 2010 Mar; 74(3):513-20. PubMed ID: 19914781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.
    Blum K; Chen TJ; Meshkin B; Waite RL; Downs BW; Blum SH; Mengucci JF; Arcuri V; Braverman ER; Palomo T
    Med Hypotheses; 2007; 69(5):1054-60. PubMed ID: 17467918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reward deficiency syndrome: genetic aspects of behavioral disorders.
    Comings DE; Blum K
    Prog Brain Res; 2000; 126():325-41. PubMed ID: 11105655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariate analysis of dopaminergic gene variants as risk factors of heroin dependence.
    Vereczkei A; Demetrovics Z; Szekely A; Sarkozy P; Antal P; Szilagyi A; Sasvari-Szekely M; Barta C
    PLoS One; 2013; 8(6):e66592. PubMed ID: 23840506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DRD2/ANKK1 TaqIA and SLC6A3 VNTR polymorphisms in alcohol dependence: association and gene-gene interaction study in a population of Central Italy.
    Mignini F; Napolioni V; Codazzo C; Carpi FM; Vitali M; Romeo M; Ceccanti M
    Neurosci Lett; 2012 Aug; 522(2):103-7. PubMed ID: 22698582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial.
    Schacht JP; Voronin KE; Randall PK; Anton RF
    Neuropsychopharmacology; 2018 May; 43(6):1247-1256. PubMed ID: 29362512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors.
    Blum K; Chen AL; Oscar-Berman M; Chen TJ; Lubar J; White N; Lubar J; Bowirrat A; Braverman E; Schoolfield J; Waite RL; Downs BW; Madigan M; Comings DE; Davis C; Kerner MM; Knopf J; Palomo T; Giordano JJ; Morse SA; Fornari F; Barh D; Femino J; Bailey JA
    Int J Environ Res Public Health; 2011 Dec; 8(12):4425-59. PubMed ID: 22408582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible interaction between MAOA and DRD2 genes associated with antisocial alcoholism among Han Chinese men in Taiwan.
    Wang TJ; Huang SY; Lin WW; Lo HY; Wu PL; Wang YS; Wu YS; Ko HC; Shih JC; Lu RB
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):108-14. PubMed ID: 17007976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effect of promoter polymorphisms in the dopamine D4 receptor and the serotonin transporter genes in heroin dependence.
    Szilagyi A; Boór K; Székely A; Gaszner P; Kalász H; Sasvári-Székely M; Barta C
    Neuropsychopharmacol Hung; 2005 Mar; 7(1):28-33. PubMed ID: 16167465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Family-based and case-control study of DRD2, DAT, 5HTT, COMT genes polymorphisms in alcohol dependence.
    Samochowiec J; Kucharska-Mazur J; Grzywacz A; Jabłoński M; Rommelspacher H; Samochowiec A; Sznabowicz M; Horodnicki J; Sagan L; Pełka-Wysiecka J
    Neurosci Lett; 2006 Dec; 410(1):1-5. PubMed ID: 17079080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do alcohol-dependent individuals with DRD2 A1 allele have an increased risk of relapse? A pilot study.
    Dahlgren A; Wargelius HL; Berglund KJ; Fahlke C; Blennow K; Zetterberg H; Oreland L; Berggren U; Balldin J
    Alcohol Alcohol; 2011; 46(5):509-13. PubMed ID: 21613303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential association of DRD2 and DAT1 genetic variation with heroin dependence.
    Hou QF; Li SB
    Neurosci Lett; 2009 Oct; 464(2):127-30. PubMed ID: 19664686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward.
    Kirsch P; Reuter M; Mier D; Lonsdorf T; Stark R; Gallhofer B; Vaitl D; Hennig J
    Neurosci Lett; 2006 Sep; 405(3):196-201. PubMed ID: 16901644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association analyses for dopamine receptor gene polymorphisms and weight status in a longitudinal analysis in obese children before and after lifestyle intervention.
    Roth CL; Hinney A; Schur EA; Elfers CT; Reinehr T
    BMC Pediatr; 2013 Nov; 13():197. PubMed ID: 24283216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.
    Blum K; Chen AL; Chen TJ; Braverman ER; Reinking J; Blum SH; Cassel K; Downs BW; Waite RL; Williams L; Prihoda TJ; Kerner MM; Palomo T; Comings DE; Tung H; Rhoades P; Oscar-Berman M
    Theor Biol Med Model; 2008 Nov; 5():24. PubMed ID: 19014506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase-A polymorphisms might modify the association between the dopamine D2 receptor gene and alcohol dependence.
    Huang SY; Lin WW; Wan FJ; Chang AJ; Ko HC; Wang TJ; Wu PL; Lu RB
    J Psychiatry Neurosci; 2007 May; 32(3):185-92. PubMed ID: 17476365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.